In another sign of biopharma's waning interest in the traditional ex vivo gene therapy approach, CSL Behring is shutti | CSL ...

Neurogene has dropped plans to keep studying the high dose of its Rett syndrome gene therapy because of an adverse event that ...

But the incumbents look set to fight to hold on to the market, with Alnylam Pharmaceuticals sharing early-phase data on its ...

A spin-out from the University of Edinburgh in Scotland is already equipped with 15 million pounds ($19 million) in seed ...

Novartis is adding another radiopharmaceutical program to its collection, penning a deal worth $745 million in biobucks for ...